Thyroid Cancer Information Center
Knowledge is power. Are you facing a new diagnosis, recurrence, living with metastatic disease, or supporting a loved one through their cancer journey? The Cancer Connect Thyroid Cancer Information Center has current, evidence-based information for you. Get the facts about thyroid cancer early detection, treatment, and survivorship, and stay up to date with ongoing thyroid cancer research that could impact your treatment decisions through our daily cancer news.
You are not alone—The CancerConnect Thyroid Cancer Community is the leading Social Media Application for Thyroid Cancer patients and caregivers seeking information, inspiration, and support in the wake of a cancer diagnosis. With over 50,000 members the network offers patients and caregivers a thriving community to support the many ongoing needs from diagnosis to survivorship. Login or register here.
Protein identified behind growth and spread; promising step for treatment research Lenvatinib; First Promising Treatment for Refractory Thyroid Cancer Patients in Years
For those who received lenvatinib, 64.8% of patients experienced a partial or complete disappearance of their cancer following treatment, and the median progression-free survival was 18.3 months, compared with 3.6 months in those who received placebo. National Thyroid Cancer Awareness Month on CancerConnect
Stay informed and get connected!
Cancer and its treatment can come with a variety of complications, some more serious... Advanced Directives
Living Wills Every competent adult has, in most cases, the freedom to accept or refuse... Caregivers
What is Caregiving and Who are Caregivers? Caregivers are individuals who provide...
Moving On Aerobics helps women regain joy of movement and physical fitness after... Where Kids Can Be Kids… And Cancer Takes a Back Seat
Cancer camps for kids provide fun and camaraderie for children facing down a cancer... Pay it Forward
Survivors become peer mentors to newly diagnosed women and offer experience, insight,...
Thyroid Cancer Clinical Trials
E-5-05 – Phase II Study of Decitabine in Patients with Metastatic Papillary Thyroid Cancer of Follicular Thyroid Cancer Unresponsive to Radioiodine.
REFMAL28-T – A PHASE I STUDY OF ORAL TEMOZOLOMIDE IN COMBINATION WITH IRINOTECAN IN PATIENT WITH REFRACTORY AND/OR ADVANCED SOLID TUMORS.-T
20050130 – An Open Label Treatment Extension Study of AMG 706